Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 4.05 USD -1.94% Market Closed
Market Cap: 105.1m USD
Have any thoughts about
Inovio Pharmaceuticals Inc?
Write Note

Inovio Pharmaceuticals Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Inovio Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Inovio Pharmaceuticals Inc
NASDAQ:INO
Total Liabilities & Equity
$107.1m
CAGR 3-Years
-42%
CAGR 5-Years
-7%
CAGR 10-Years
-2%
Abbvie Inc
NYSE:ABBV
Total Liabilities & Equity
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities & Equity
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Liabilities & Equity
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities & Equity
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities & Equity
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%
No Stocks Found

Inovio Pharmaceuticals Inc
Glance View

Market Cap
105.5m USD
Industry
Biotechnology

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.

INO Intrinsic Value
5.93 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Inovio Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
107.1m USD

Based on the financial report for Sep 30, 2024, Inovio Pharmaceuticals Inc's Total Liabilities & Equity amounts to 107.1m USD.

What is Inovio Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-2%

Over the last year, the Total Liabilities & Equity growth was -45%. The average annual Total Liabilities & Equity growth rates for Inovio Pharmaceuticals Inc have been -42% over the past three years , -7% over the past five years , and -2% over the past ten years .

Back to Top